MBBS (NUS, Singapore) 2005, M Med (Int Med) (NUS, Singapore) 2009, MRCP (UK) (RCP, United Kingdom) 2009, FRACP (RACP, Australia) 2014, PhD (U of Melbourne, Australia) 2020
Medical Oncology, NHG Cancer Institute
Medical Oncology, Tan Tock Seng Hospital
Medical Oncology, Woodlands Hospital
Dr Chia Puey Ling is a Senior Consultant with the Department of Medical Oncology at Tan Tock Seng Hospital (TTSH) with subspecialty interest in thoracic and genitourinary oncology.
After completing her basic physician training in Singapore and obtaining membership of the Royal Colleges of Physicians of the United Kingdom (MRCP) and Master of Medicine (Internal Medicine) Singapore, she subsequently underwent advanced specialist training in Medical Oncology in Melbourne, Australia. She obtained the Fellowship of the Royal Australasian College of Physicians (FRACP) with speciality training in Medical Oncology and completed further PhD research related to thoracic oncology which is her field of interest.
Dr Chia received the International Association for the Study of Lung Cancer (IASLC) Fellowship Award and the University of Melbourne Postgraduate Award and completed a PhD research on the study of tumour microenvironment and biomarkers in malignant mesothelioma for oncogenic targeted therapies.
Publications
1. Lung Cancer in Singapore.
2. Editorial Comment to Impact of neoadjuvant chemotherapy on survival and recurrence patterns after robot-assisted radical cystectomy for muscle-invasive bladder cancer: Results from the International Robotic Cystectomy Consortium.
3. Editorial Comment to Impact of the coronavirus disease-2019 pandemic on the number of patients undergoing radical nephroureterectomy and postoperative adjuvant systematic therapy for upper tract urothelial carcinomas in Japan: A multicenter retrospective study
4. Targeting and efficacy of novel mAb806-Antibody-Drug Conjugates in maligt mesothelioma
5. Expression of EGFR and conformational forms of EGFR in malignant pleural mesothelioma and its impact on survival
6. Analysis of angiogenic and stromal biomarkers in a large mesothelioma cohort
7. Combination of Osimertinib and Pembrolizumab successfully overcome dual resistances in a patient with advanced adenocarcinoma of the lung, a case report
8. Resectable non-small cell lung cancer: an evolving landscape.
9. An approach to genetic testing in patients with metastatic castration-resistant prostate cancer in Singapore
10. Tepotinib + osimertinib for EGFR mutant (EGFR m) NSCLC with MET amplification ( MET amp) after first-line (1L) osimertinib.
11. Management of Oncogene Driven Locally Advanced Unresectable Non-small Cell Lung Cancer
12. Management of HER2 alterations in non-small cell lung cancer – The past, present, and future
13. Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial.
